Keros Therapeutics to Showcase Innovations at Upcoming Events
Keros Therapeutics, Inc. (NASDAQ: KROS), a pioneering biopharmaceutical company, is set to make waves in the healthcare sector with its upcoming presentations by CEO Jasbir S. Seehra, Ph.D. Keros, dedicated to developing novel therapeutics, focuses on disorders tied to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, promoting a brighter future for many patients facing complex health challenges.
Piper Sandler 36th Annual Healthcare Conference
Keros will be featured at the esteemed Piper Sandler Annual Healthcare Conference, taking place soon. This event is an essential platform where industry leaders come together to share insights and advancements.
- Date and Time: Early December
- Format: Fireside Chat Presentation
Evercore HealthCONx Conference Participation
Another significant event is the Evercore HealthCONx Conference, where Keros aims to highlight its innovative approaches and commitment to patient care. The presentation format will also be a fireside chat, promoting an engaging atmosphere for dialogue.
- Date and Time: Early December
- Format: Fireside Chat Presentation
About Keros Therapeutics
Keros Therapeutics, Inc. stands at the forefront of clinical-stage biopharmaceuticals, specializing in therapeutics that tackle diseases associated with TGF-ß proteins. These proteins are critical in regulating tissue growth and maintenance across various systems in the body, including blood, bone, and muscle. Keros aims to capitalize on this molecular understanding to craft protein-based therapies that could fundamentally alter treatment paradigms for patients.
Expanding Therapeutic Portfolio
Keros has made remarkable advancements with its lead product candidate, elritercept (KER-050), targeting cytopenias—deficiencies of blood cells such as anemia and thrombocytopenia in patients suffering from myelodysplastic syndromes and myelofibrosis. This innovative approach underscores the company’s commitment to improving patient outcomes and enhancing their quality of life.
Additionally, Keros is actively developing its second candidate, cibotercept (KER-012), aimed at addressing pulmonary arterial hypertension, a condition posing serious cardiovascular risks. Moreover, KER-065 is in the pipeline for treating obesity and neuromuscular disorders, showcasing Keros' dedication to diverse therapeutic challenges.
Engagement with Investors
Investor engagement is another critical aspect of Keros’ strategy. The company is proactive in providing insights and updates on its recent advancements. Following each presentation, archived replays will be available on the Keros website, ensuring that stakeholders remain informed about the company's progress and commitments.
Contacting Keros Therapeutics
For investors eager to connect, Keros Therapeutics has established channels for inquiries. Justin Frantz is the point of contact—he can be reached at 617-221-6042 for direct communication regarding investing and corporate developments.
Frequently Asked Questions
What is Keros Therapeutics focused on?
Keros Therapeutics specializes in developing novel therapeutics for disorders linked to dysfunctional TGF-ß protein signaling.
Who is presenting at the upcoming conferences?
The presentations will be led by Keros Therapeutics' CEO, Jasbir S. Seehra, Ph.D.
Where can I find recordings of the presentations?
Archived replays will be available on the Keros Therapeutics website after the events conclude.
What are the main product candidates developed by Keros?
The lead candidates include elritercept (KER-050) for cytopenias, cibotercept (KER-012) for pulmonary arterial hypertension, and KER-065 for obesity and neuromuscular diseases.
How can investors reach out to Keros Therapeutics?
Investors can contact Justin Frantz at Keros via phone for any inquiries related to the company.
